CD34+-Selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 3, 2014, Pages 382-386

  Klyuchnikov, Evgeny ^a   El Cheikh, Jean ^b   Sputtek, Andreas ^a   Lioznov, Michael ^a   Calmels, Boris ^b   Furst, Sabine ^b   Chabannon, Christian ^b   Crocchiolo, Roberto ^b   Lemarié, Claude ^b   Faucher, Catherine ^b   Bacher, Ulrike ^a   Alchalby, Haefaa ^a   Stübig, Thomas ^a   Wolschke, Christine ^a   Ayuk, Francis ^a   Reckhaus, Marie Luise ^a   Blaise, Didier ^b   Kröger, Nicolaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b INSTITUT PAOLI CALMETTES   (France)

Author keywords

Allogeneic hematopoietic stem cell transplantation (HSCT); CD34+ selected cells; Poor graft function; Stem cell boost

Indexed keywords

HEMOGLOBIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; BODY WEIGHT; CD3+ T LYMPHOCYTE; CD34 SELECTION; CD34 STEM CELL BOOST; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DISEASE CLASSIFICATION; FEMALE; GRAFT DYSFUNCTION; GRAFT RECIPIENT; HEMATOLOGIC MALIGNANCY; HUMAN; INCIDENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; NEUTROPHIL; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; POOR GRAFT FUNCTION; RETROSPECTIVE STUDY; THROMBOCYTE; TREATMENT OUTCOME; YOUNG ADULT;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT); CD34(+)-SELECTED CELLS; POOR GRAFT FUNCTION; STEM CELL BOOST;

ACUTE DISEASE; ADULT; ANTIGENS, CD3; ANTIGENS, CD34; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; NEUTROPHILS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84896864241     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.11.034     Document Type: Article

References (19)

1. Gaya A., Urbano-Ispizua A., Fernandez-Aviles F., et al. Anemia associated with impaired erythropoietin secretion after allogeneic stem cell transplantation: incidence, risk factors,and response to treatment. Biol Blood Marrow Transplant 2008, 14:880-887.
2. Ringden O., Hassan Z., Karlsson H., et al. Granulocyte colony-stimulating factor induced acute and chronic graft-versus-host disease. Transplantation 2010, 90:1022-1029.
3. Guardiola P., Kuentz M., Garban F., et al. Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. French Society of Bone Marrow Transplantation. Br J Haematol 2000, 111:292-302.
4. Chewning J.H., Castro-Malaspina H., Jakubowski A., et al. Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure. Biol Blood Marrow Transplant 2007, 13:1313-1323.
5. Jabbour E., Rondon G., Anderlini P., et al. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. Bone Marrow Transplant 2007, 40:431-435.
6. Remberger M., Ringden O., Ljungman P., et al. Booster marrow or blood cells for graft failure after allogeneic bone marrow transplantation. Bone Marrow Transplant 1998, 22:73-78.
7. Min C.K., Kim D.W., Lee J.W., et al. Additional stem cell therapy for graft failure after allogeneic bone marrow transplantation. Acta Haematol 2000, 104:185-192.
8. Larocca A., Piaggio G., Podesta M., et al. Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. Haematologica 2006, 91:935-940.
9. Mohty M., Faucher C., Chabannon C., et al. CD34(+) immunoselected cells for poor graft function following allogeneic BMT. Cytotherapy 2000, 2:367-370.
10. Milone G., Tornello A., Leotta S., et al. CD34+ selected haematopoietic stem cell (HSC) not preceded by any immunosuppressive therapy as effective treatment for graft failure. Bone Marrow Transplant 2005, 35:521-522.
11. Oyekunle A., Koehl U., Schieder H., et al. CD34(+)-selected stem cell boost for delayed or insufficient engraftment after allogeneic stem cell transplantation. Cytotherapy 2006, 8:375-380.
12. Glaspy J.A. Erythropoietin in cancer patients. Annu Rev Med 2009, 60:181-192.
13. Gurion R., Shacham-Abulafia A., Shpilberg O., Raanani P. The use of myeloid colony-stimulating factors in hematologic malignancies:the role of systematic reviews and meta-analyses. Acta Haematol 2011, 125:68-79.
14. Walenda T., Bokermann G., Ventura Ferreira M.S., et al. Synergistic effects of growth factors and mesenchymal stromal cells for expansion of hematopoietic stem and progenitor cells. Exp Hematol 2011, 39:617-628.
15. Bernardo M.E., Cometa A.M., Locatelli F. Mesenchymal stromal cells: a novel and effective strategy for facilitating engraftment and accelerating hematopoietic recovery after transplantation?. Bone Marrow Transplant 2012, 47:323-329.
16. Liu X., Wu M., Peng Y., et al. Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: a pilot prospective study. Cell Transplant 2013, [Epub ahead of print].
17. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974, 18:295-304.
18. Sullivan K., Shulman H., Storb R., et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981, 57:267-276.
19. Scrucca L., Santucci A., Aversa F. Competing risk analysis using R: aneasy guide for clinicians. Bone Marrow Transplant 2007, 40:381-387.